Our new technical analysis of Artelo Biosciences (NASDAQ:ARTL)

ARTL
 Stock
  

USD 3.19  0.27  7.80%   

While some baby boomers are getting worried about healthcare space, it is reasonable to summarize Artelo Biosciences against economic and market trends. As expected, Artelo Biosciences is starting to reaffirm its true potential as stakeholders are becoming more and more confident in the future outlook. A great deal of the actions of the company stock price movements has been a reflection of what is happening in the market overall. Sluggish basic indicators of the company may also denote signs of medium-term losses for Artelo stakeholders. Artelo Biosciences is scheduled to announce its earnings today. The upcoming quarterly report is expected on the 12th of April 2022.
Published over three months ago
View all stories for Artelo Biosciences | View All Stories
This firm's average rating is Strong Buy from 3 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Artelo Biosciences market sentiment investors' perception of the future value of Artelo. Let us look at a few aspects of Artelo technical analysis. The company has price-to-book (P/B) ratio of 0.88. Some equities with similar Price to Book (P/B) outperform the market in the long run. Artelo Biosciences recorded a loss per share of 0.4. The entity had not issued any dividends in recent years.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Artelo Biosciences. In general, we focus on analyzing Artelo Biosciences stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Artelo Biosciences's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Artelo Biosciences's intrinsic value. In addition to deriving basic predictive indicators for Artelo Biosciences, we also check how macroeconomic factors affect Artelo Biosciences price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Artelo Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Artelo Biosciences in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Artelo Biosciences. Your research has to be compared to or analyzed against Artelo Biosciences' peers to derive any actionable benefits. When done correctly, Artelo Biosciences' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Artelo Biosciences.

How important is Artelo Biosciences's Liquidity

Artelo Biosciences financial leverage refers to using borrowed capital as a funding source to finance Artelo Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Artelo Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Artelo Biosciences's total debt and its cash.

How does Artelo utilize its cash?

To perform a cash flow analysis of Artelo Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Artelo Biosciences is receiving and how much cash it distributes out in a given period. The Artelo Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Detailed Perspective On Artelo Biosciences

The company has a beta of 1.807. Let's try to break down what Artelo's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Artelo Biosciences will likely underperform. The beta indicator helps investors understand whether Artelo Biosciences moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Artelo deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. Artelo Biosciences reported the previous year's revenue of 212.82 M. Net Loss for the year was (8.55 M) with profit before overhead, payroll, taxes, and interest of 83.01 M.

Are Artelo Biosciences technical ratios showing a turnaround?

New Risk Adjusted Performance is up to -0.03. Price may pull down again. Artelo Biosciences exhibits very low volatility with skewness of 0.05 and kurtosis of 0.55. However, we advise investors to further study Artelo Biosciences technical indicators to make sure all market info is available and is reliable. Artelo Biosciences is a potential penny stock. Although Artelo Biosciences may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Artelo Biosciences. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Artelo instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Bottom Line On Artelo Biosciences

While some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Artelo Biosciences may offer a potential longer-term growth to stakeholders. To sum up, as of the 11th of April 2022, we believe that at this point, Artelo Biosciences is undervalued with close to average chance of financial distress within the next 2 years. However, our present Buy-Hold-Sell recommendation on the company is Strong Sell.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Artelo Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com